Subscribe To
Kineta reports third quarter 2023 financial results and provides corporate update
Announced positive KVA12123 monotherapy safety data from its ongoing phase 1/2 VISTA-101 clinical trial Enrolled the first patient of KVA12123 in comb...
November 3, 2023, 8:01 pm
Atossa therapeutics' (z)-endoxifen being evaluated as alternative treatment for ductal carcinoma in situ
Atossa Therapeutics Inc (NASDAQ:ATOS)'s selective estrogen receptor modulator (Z)-endoxifen is being ev...
October 30, 2023, 3:11 pm
Reneo pharmaceuticals announces poster presentation at upcoming scientific meetings
IRVINE, Calif., Oct. 25, 2023 (GLOBE NEWSWIRE) — Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical stage pharmaceutical company focused on the ...
October 25, 2023, 11:50 am
Carisma to present first results from in vivo car-m collaboration with moderna at sitc 2023
-Late-breaking abstract to be presented on November 3 rd at 11:30 am PT highlighting pre-clinical data with Moderna -Two additional pre-clinical data ...
October 25, 2023, 9:11 am
Altimmune to present new data on the anti-inflammatory and anti-fibrotic properties of pemvidutide in a late-breaking presentation at the liver meeting® 2023
GAITHERSBURG, Md., Oct. 25, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that n...
October 25, 2023, 7:30 am
Merck's keytruda shows positive results in confirmatory trial as treatment for rare form of esophageal cancer
Merck & Co. MRK, -1.53% said Friday a late-stage trial of its blockbuster cancer drug Keytruda plus trastuzumab, fluoropyrimidine- and platinum-contai...
October 20, 2023, 8:13 am
Why is viking therapeutics (vktx) stock moving today?
Viking Therapeutics (NASDAQ: VKTX ) stock is on the move Wednesday as the clinical-stage biopharmaceutical company reveals data from a clinical trial....
October 18, 2023, 10:01 am
Viking therapeutics joins weight loss drug bandwagon as trial data impresses
Viking Therapeutics (NASDAQ:VKTX) shares shot up 12% in overnight US trading as the drug developer revealed more impressive trial data from a treatmen...
October 18, 2023, 7:06 am
Arvinas and pfizer announce upcoming vepdegestrant (arv-471) poster presentation at esmo congress 2023
NEW HAVEN, Conn. and NEW YORK, Oct. 15, 2023 (GLOBE NEWSWIRE) — Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE: PFE) today announced they will p...
October 15, 2023, 10:05 pm
Pharvaris to present at the apaaaci 2023 international conference
ZUG, Switzerland, Oct. 13, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin B2 ...
October 13, 2023, 6:50 am
Immunic presents data from phase 2 study of vidofludimus calcium in relapsing-remitting ms
Immunic Inc (NASDAQ:IMUX) announced that data from its Phase 2 EMPhASIS trial of nuclear receptor-relat...
October 11, 2023, 10:11 am
Pharvaris to present at the ciic fall 2023 conference
ZUG, Switzerland, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-...
October 4, 2023, 7:34 am
Cancer drug approval? 3 biotech stocks on the brink of breakthroughs
Autologous chimeric antigen receptor T cell therapy is 0ne of the most promising, relatively new types ...
October 2, 2023, 7:09 pm
$vktx: consolidation in viking therapeutics provides an opportunity
Viking Therapeutics Inc. is an innovative biotechnology company developing novel therapeutics for metabolic and endocrine diseases. Metabolic and rare...
October 2, 2023, 6:17 pm
Structure therapeutics stock soars on positive weight loss data
Structure Therapeutics Inc shares surged 34% to $50.34 in midday trading on Friday after the clinical-stage global biopharmaceutical company announced...
September 29, 2023, 12:55 pm
Pharvaris to participate in the 2023 cantor global healthcare conference
ZUG, Switzerland, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-...
September 19, 2023, 6:50 am
Vigil neuroscience: interesting early data, wait for phase 2
Vigil Neuroscience is developing medicines for neurodegenerative diseases by restoring microglial function. Their lead candidate, VGL101, is a monoclo...
September 18, 2023, 2:38 pm
Io therapeutics, inc., announces publication of data on a novel compound promoting anti-cancer immune responses
SPRING, Texas, Sept. 12, 2023 (GLOBE NEWSWIRE) — Io Therapeutics, Inc., announced today the publication in Scientific Reports – Nature Publishing ...
September 12, 2023, 4:43 am
Pharvaris to present at the 18th german allergy congress
ZUG, Switzerland, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-...
September 6, 2023, 6:51 am
Pharvaris to participate in the morgan stanley 21st annual global healthcare conference
ZUG, Switzerland, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-...
September 6, 2023, 6:50 am